gastric inhibitory peptide formerly termed "gastric inhibitory peptide - Gastric inhibitory peptidereleased by has been demonstrated to inhibit gastric acid secretion Unveiling the Role of Gastric Inhibitory Peptide in Human Physiology

Gastric inhibitory peptidestimulus Gastric inhibitory peptide (GIP), a crucial hormone primarily produced in the duodenum and intestine, plays a significant role in regulating glucose homeostasis and influencing various physiological processes. Once referred to as "gastric inhibitory peptide," this peptide hormone is now more widely known as glucose-dependent insulinotropic polypeptide (GIP).2025年2月19日—GIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42 amino acid peptide hormone ... Its discovery in 1973 marked a significant step in understanding the complex interplay of hormones in digestion and metabolismGIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42-amino-acid peptide hormone synthesized in and ....

GIP belongs to the secretin family of hormones and is a 42-amino acid polypeptide synthesized by K cells located in the proximal small intestine. Its release is primarily stimulated by the presence of nutrients, particularly carbohydrates and fats, in the intestinal lumen following a meal. This nutrient-induced secretion is the cornerstone of its function as an incretin hormone.

The Incretin Effect and Insulin Secretion

One of the most well-established roles of gastric inhibitory peptide is its contribution to the "incretin effect." This phenomenon describes the observation that oral glucose administration elicits a significantly greater insulin response compared to intravenous glucose administration, even when blood glucose levels are matched. GIP accounts for a substantial portion, estimated between 60% to 80%, of this incretin effect.

Upon binding to its specific receptor, the gastric inhibitory polypeptide receptor (GIP-R), which is a protein, GIP potently stimulates insulin secretion from pancreatic beta cells. This stimulation is glucose-dependent, meaning that GIP enhances insulin release primarily when blood glucose levels are elevated, thereby preventing hypoglycemia.Gastric inhibitory polypeptide, also known as glucose-dependent insulinotropic polypeptide (GIP),is a 42-amino acid hormone that stimulates insulin(INS; ... The GIP protein acts as a high-affinity agonist of its receptor, with an EC50 reported as 0.Released in response to food,GIP stimulates insulin secretion from the pancreasand also influences appetite and energy balance. It works alongside GLP-1 and ...81 nM, highlighting its potent biological activity.

Beyond Insulin: Other Physiological Influences

While its role in insulin secretion is paramount, gastric inhibitory peptide exerts other notable physiological effects. Historically, it was named for its ability to inhibit gastric acid secretion. Indeed, GIP was shown to inhibit acid secretion in animal models, and it is described as a hormone secreted by cells of the intestinal mucosa that blocks the secretion of hydrochloric acid into the stomach. However, research suggests that its role as a relatively poor inhibitor of gastric acid secretion in humans may be less pronounced than its insulinotropic effects.Gastric Inhibitory Polypeptide (GIP) is defined asa 42-amino-acid gastrointestinal hormonethat mediates insulin secretion in response to nutrient intake, ...

Furthermore, GIP has been implicated in influencing appetite and energy balance. Studies have explored the role of GIP in the regulation of GLP-1 satiety and nausea, suggesting a complex interplay between these two key incretin hormones.What are GIP inhibitors and how do they work? GIP and GLP-1 (glucagon-like peptide-1) are recognized as the two primary incretin hormones secreted from the intestine upon nutrient ingestion. The synergistic action of GIP and GLP-1 is crucial for maintaining glucose metabolism.

Emerging research also points to the potential involvement of GIP in conditions like type 2 diabetes. GIP may play a role in the initiation of impaired β-cell function in first-degree relatives of type 2 diabetic patients, indicating a potential genetic predisposition or early-stage dysfunction related to GIP signaling.

Therapeutic Implications: GIP Inhibitors and Dual-Acting Agents

The significant physiological roles of gastric inhibitory peptide have spurred interest in its therapeutic potential. GIP inhibitors, also known as gastric inhibitory polypeptide receptor antagonists, are a class of drugs designed to target the GIP receptorGIP is an essential regulator of insulin secretion and glucose homeostasis. It is a high affinity agonist of its receptor (EC50 = 0.81 nM) that inhibits .... These antagonists, such as GIP(3-30)NH2, work by blocking the action of GIP, potentially influencing metabolic pathways.

More recently, advancements have led to the development of dual-acting treatments that target both GLP-1 and GIP. These agents, exemplified by treatments similar to Eli Lilly's offerings, aim to leverage the combined benefits of both incretin hormones for managing conditions like obesity. A notable example is the investigational drug CT-388, a dual-acting treatment targeting both GLP-1 and gastric inhibitory peptide, which has shown significant weight loss in clinical trials.

In summary, gastric inhibitory peptide (GIP), or glucose-dependent insulinotropic polypeptide, is a vital gastrointestinal hormone with multifaceted functions2025年2月19日—GIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42 amino acid peptide hormone .... Its primary role as a potent stimulator of insulin secretion is critical for glucose homeostasis. While its historical designation highlighted its inhibitory effects on gastric acid, its modern understanding emphasizes its integral part in the incretin system and its emerging relevance in metabolic disease and therapeutic interventions.GIP is an essential regulator of insulin secretion and glucose homeostasis. It is a high affinity agonist of its receptor (EC50 = 0.81 nM) that inhibits ...